Unknown

Dataset Information

0

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.


ABSTRACT: Antibody therapy targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy induces a high rate of immune-related adverse events. The underlying factors that may influence anti-CTLA4 antibody therapy are not well defined. We report the impact of a cancer-derived immune modulator, the human-soluble natural killer group 2D (NKG2D) ligand sMIC (soluble major histocompatibility complex I chain-related molecule), on the therapeutic outcome of anti-CTLA4 antibody using an MIC transgenic spontaneous TRAMP (transgenic adenocarcinoma of the mouse prostate)/MIC tumor model. Unexpectedly, animals with elevated serum sMIC (sMIChi) responded poorly to anti-CTLA4 antibody therapy, with significantly shortened survival due to increased lung metastasis. These sMIChi animals also developed colitis in response to anti-CTLA4 antibody therapy. Coadministration of an sMIC-neutralizing monoclonal antibody with the anti-CTLA4 antibody alleviated treatment-induced colitis in sMIChi animals and generated a cooperative antitumor therapeutic effect by synergistically augmenting innate and adoptive antitumor immune responses. Our findings imply that a new combination therapy could improve the clinical response to anti-CTLA4 antibody therapy. Our findings also suggest that prescreening cancer patients for serum sMIC may help in selecting candidates who will elicit a better response to anti-CTLA4 antibody therapy.

SUBMITTER: Zhang J 

PROVIDER: S-EPMC5435412 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Zhang Jingyu J   Liu Dai D   Li Guangfu G   Staveley-O'Carroll Kevin F KF   Graff Julie N JN   Li Zihai Z   Wu Jennifer D JD  

Science advances 20170517 5


Antibody therapy targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy induces a high rate of immune-related adverse events. The underlying factors that may influence anti-CTLA4 antibody therapy are not well defined. We report the impact of a cancer-derived immune modulator, the human-soluble natural killer group 2D (NKG2D) ligand sMIC (soluble major hist  ...[more]

Similar Datasets

| S-EPMC7285527 | biostudies-literature
| S-EPMC8881216 | biostudies-literature
2021-10-13 | E-MTAB-11084 | biostudies-arrayexpress
2021-10-29 | E-MTAB-11117 | biostudies-arrayexpress
| S-EPMC2722284 | biostudies-literature
| S-EPMC6290683 | biostudies-literature
| S-EPMC3100196 | biostudies-literature
| S-EPMC7821912 | biostudies-literature
| S-EPMC4344968 | biostudies-literature
| S-EPMC8528076 | biostudies-literature